NCT07190053Not yet recruiting
Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.
Long-term Treatment Strategies and Effectiveness of Secukinumab in Juvenile Idiopathic Arthritis Patients of Psoriatic and Enthesitis-related Arthritis Categories: Secondary Use of Data and Primary Data Collection From the German BIKER Registry
Source: ClinicalTrials.gov · Last updated 24 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this study is to understand the long-term treatment strategies in children and adolescents diagnosed with ERA or JPsA who received secukinumab and achieved inactive disease and to evaluate the long-term treatment effectiveness of secukinumab in the ERA or JPsA patients in the postauthorization setting.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 12 Jun 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 18 Sept 2029
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriatic arthritis
- NCT number
- NCT07190053
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Dec 2025 to the primary completion date, 18 Sept 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients taking other biologic immunomodulating agent(s) or Janus kinase (JAK) inhibitors concomitantly with secukinumab at index date.
Other
- Patients participating in any interventional trials at index date.
Who the study is looking for
- In the BIKER registry, males and females ≥ 6 years old and ≤ 17 years old diagnosed with ERA according to the ILAR-criteria or JPsA according to the ILAR or the Vancouver criteria, who initiated at least one dose of secukinumab after it was approved in Germany and according to the label.
- Written informed consent from parent/legal guardian and assent from minor patient (11-17 years of age) for participating in the BIKER registry and for this study enrolment.
Age in the registry: 6 years to 17 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.